28 Views | 25 Downloads
Correspondence: David Avigan, Hematologic Malignancies, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215. E-mail: davigan@bidmc.harvard.edu
Author contributions: D.J. Chung: Conceptualization, investigation, methodology, writing–original draft, writing–review and editing. N. Shah: Conceptualization, investigation, methodology, writing–original draft, writing–review and editing. J. Wu: Data curation, formal analysis, investigation, methodology, writing–original draft, writing–review and editing. B. Logan: Investigation, methodology, writing–review and editing. L. Bisharat: Investigation, methodology, writing–review and editing. N. Callander: Conceptualization, investigation, methodology, writing–original draft, writing–review and editing. G. Cheloni: Conceptualization, investigation, methodology, writing–original draft, writing–review and editing. K. Anderson: Investigation, methodology, writing–review and editing. T. Chodon: Investigation, methodology, writing–review and editing. B. Dhakal: Investigation, methodology, writing–review and editing. S. Devine: Investigation, methodology, writing–review and editing. P. Somaiya Dutt: Investigation, methodology, writing–review and editing. Y. Efebera: Investigation, methodology, writing–review and editing. N. Geller: Investigation, methodology, writing–review and editing. H. Ghiasuddin: Investigation, methodology, writing–review and editing. P. Hematti: Investigation, methodology, writing–review and editing. L. Holmberg: Investigation, methodology, writing–review and editing. A. Howard: Investigation, methodology, writing–review and editing. B. Johnson: Conceptualization, investigation, methodology, writing–original draft, writing–review and editing. D. Karagkouni: Conceptualization, investigation, methodology, writing–original draft, writing–review and editing. H.M. Lazarus: Investigation, methodology, writing–review and editing. E. Malek: Investigation, methodology, writing–review and editing. P. McCarthy: Investigation, methodology, writing–review and editing. D. McKenna: Investigation, methodology, writing–review and editing. A. Mendizabal: Investigation, methodology, writing–review and editing. A. Nooka: Investigation, methodology, writing–review and editing. N. Munshi: Investigation, methodology, writing–review and editing. L. O'Donnell: Investigation, methodology, writing–review and editing. A.P. Rapoport: Investigation, methodology, writing–review and editing. J. Reese: Investigation, methodology, writing–review and editing. J. Rosenblatt: Investigation, methodology, writing–review and editing. R. Soiffer: Investigation, methodology, writing–review and editing. D. Stroopinsky: Investigation, methodology, writing–review and editing. L. Uhl: Conceptualization, investigation, methodology, writing–original draft, writing–review and editing. I.S. Vlachos: Conceptualization, investigation, methodology, writing–original draft, writing–review and editing. E.K. Waller: Investigation, methodology, writing–review and editing. J.W. Young: Conceptualization, investigation, methodology, writing–original draft, writing–review and editing. M.C. Pasquini: Conceptualization, investigation, methodology, writing–original draft, writing–review and editing. D. Avigan: Conceptualization, data curation, formal analysis, investigation, methodology, writing–original draft, writing–review and editing.
Competing interests: N. Shah reports grants from Celgene/BMS, Janssen, Bluebird Bio, Sutro Biopharma, Teneobio, Poseida, Nektar, and Precision Biosciences, and other support from GSK, Amgen, Indapta Therapeutics, Sanofi, CareDx, Kite, Karyopharm, Oncopeptides, CSL Behring, Allogene, and AstraZeneca outside the submitted work. K. Anderson reports personal fees from Pfizer, AstraZeneca, and Janssen and other support from C4 Therapeutics, Dynamic Cell Therapies, Window Therapeutics, Starton Therapeutics, NextRNA, and Oncopep outside the submitted work. B. Dhakal reports grants and personal fees from Sanofi, Janssen, GSK, and BMS; personal fees from Genentech, Pfizer, Arcellx, and Karyopharm; and grants from Carsgen outside the submitted work. L. Holmberg reports grants from Seattle Genetics, Sanofi, Millennium-Takeda, Bristol-Myers Squibb, Merck, and Iteos outside the submitted work as well as royalties from UpToDate. H.M. Lazarus reports personal fees from Partner Therapeutics and Bristol-Myers Squibb outside the submitted work. E. Malek served on advisory boards for Takeda, Celgene, Janssen, Sanofi, Karyopharm, and Adaptive Biotechnology; is a speaker for Amgen, Takeda, Bristol-Myers Squibb, Karyopharm, and Adaptive Biotechnology; and received research funding from Medpacto Pharmaceuticals. P. McCarthy reports other support from Bristol-Myers Squibb, Janssen, Oncopeptides, Karyopharm, Starton, Partner Therapeutics, Takeda, BeiGene, HSC Acquisition, and GSK outside the submitted work. D. McKenna reports grants from NIH during the conduct of the study. A. Nooka reports personal fees from Adaptive Biotechnologies, Amgen, Beyond Spring, Bristol-Myers Squibb, Cellectar Biosciences, GlaxoSmithKline, Janssen, Karyopharm, Oncopeptides, ONK Therapeutics, Pfizer, Sanofi, Secura Bio, and Takeda outside the submitted work. N. Munshi reports personal fees from AbbVie, Adaptive, Amgen, Bristol-Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Legend, Novartis, Pfizer, Takeda, and Dana-Farber Cancer Institute and personal fees and other support from OncoPep outside the submitted work. L. O'Donnell reports grants from NIH/NCI/BMTCTN during the conduct of the study. J. Rosenblatt reports grants from MMRF and Celgene during the conduct of the study as well as grants and other support from BMS; grants from Sanofi and Karyopharm; other support from Attivare, Parexel, Clario/Bioclinica, Amgen, Merck, Kite Pharma, Partner Tx, Imaging Endpoint, Dava Oncology, and Wolters Kluwer Health, Inc.; and grants and nonfinancial support from Celgene outside the submitted work. In addition, J. Rosenblatt has a patent for PCT/US2021059199 pending. R. Soiffer reports personal fees from BMS, Vor, Gilead, Astellas, Smart Immune, Cugene, Jasper, BlueSphere Bio, and Daiichi Sankyo outside the submitted work. D. Stroopinsky reports other support from Takeda Pharmaceuticals during the conduct of the study. I.S. Vlachos reports grants from NCI, NHLBI, Singular Genomics, Harvard Stem Cell Institute, and Massachusetts Life Sciences Center and personal fees from Mosaic, Guidepoint Global, and Next RNA and outside the submitted work. E.K. Waller reports grants from BMTCTN during the conduct of the study. M.C. Pasquini reports grants from Novartis, Kite Pharma, and Janssen and grants and personal fees from Bristol-Myers Squibb outside the submitted work. D. Avigan reports grants from MMRF and CTN (NIHLBI) during the conduct of the study as well as grants and other support from Celgene and Kite Pharma; grants from Pharmacyclics; and other support from Juno, Partners TX, Karyopharm, BMS, Aviv MedTech Ltd., Takeda, Legend Bio Tech, Chugai, Caribou Biosciences, Janssen, Parexel, Sanofi, and Kowa outside the submitted work. In addition, D. Avigan has as a patent for Personalized Cancer Vaccine and CAR T cells (PCT/US2021/059199) pending. No disclosures were reported by the other authors.
Support for this study was provided by grants #U10HL069294 and #U24HL138660 to the Blood and Marrow Transplant Clinical Trials Network from the National Heart, Lung, and Blood Institute and the National Cancer Institute along with contributions by Celgene Corporation and the Multiple Myeloma Research Fund.
The publication costs of this article were defrayed in part by the payment of publication fees. Therefore, and solely to indicate this fact, this article is hereby marked “advertisement” in accordance with 18 USC section 1734.
©2023 The Authors; Published by the American Association for Cancer Research